– Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit […]
Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseasesChondrial Therapeutics’ lead asset, CTI-1601, currently […]